Lymphocyte apheresis for chimeric antigen receptor T‐cell manufacturing in children and young adults with leukemia and neuroblastoma

Francesco Ceppi(University of Lausanne), Rebecca Gardner(Seattle Children's Hospital), Julie Rivers(Seattle Children's Hospital), Meghan Delaney(Children's National), Stephanie Mgebroff(Bloodworks Northwest), Navin Pinto(Seattle Children's Hospital), Naomi Linn(Bloodworks Northwest), Catherine Lindgren(Unknown), Colleen Annesley(Unknown), Julie R. Park(Seattle Children's Hospital)
Transfusion
March 13, 2018
10.1111/trf.14569
Cited by 93

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Current concepts in the diagnosis and management of cytokine release syndrome
|Blood|2014|2.8k
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
|Blood|2008|719
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
|Blood|2012|530
Effects of Red-Cell Storage Duration on Patients Undergoing Cardiac Surgery
|New England Journal of Medicine|2015|489